Frequently Asked Questions
The accuracy of MyPath Melanoma has been assessed in multiple studies. The sensitivity and specificity of MyPath Melanoma have been reported as 90-97% and 89-86% respectively.
Castle Biosciences operates clinical laboratories in Phoenix and Pittsburgh. The Company’s laboratories are College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified, reflecting the Company’s commitment to high-quality standards and excellence in patient care. Castle's laboratories are licensed to perform tests throughout the United States.
The DecisionDx-SCC test sample is taken from your original biopsy or surgery, so there is no need for another procedure. Once completed, test results are sent directly to your healthcare provider.
The DecisionDx-SCC test result provides a genomic-based determination of your tumor’s likelihood to metastasize within the next 3 years. The test classifies Class 1 (low), Class 2A (moderate), and Class 2B (high) biological risk of metastasis. Most patients have low or moderate biological risk.
The MyPath Melanoma GEP test will return a result of suggestive of benign, intermediate, or suggestive of malignant. The results are incorporated with all other clinical and pathological findings to inform a more definitive diagnosis and guide patient management.
Only a physician, physician assistant, or nurse practitioner can order MyPath Melanoma.
Only a physician, physician assistant, or nurse practitioner can order a TissueCypher test.
Castle Biosciences is a molecular diagnostics company focused on improving health through innovative tests that guide patient care. Castle’s current portfolio of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions are designed to provide personalized, clinically actionable information to patients and clinicians to inform treatment decisions and improve health outcomes. Additionally, Castle has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. Our tests provide patients and their doctors with critical information to help guide the management of their disease. You can get more information about insurance coverage, claims processing and financial assistance by calling 866-788-9007 and selecting option #3 or by emailing.
Castle Biosciences works with all insurance providers, including Medicare, commercial insurers, and the VA, to secure payment coverage for tests. Castle will submit insurance claims and manage the insurance billing process on behalf of patients. The company also sponsors an industry-leading Patient Assistance Program with the belief that quality care should not depend on financial considerations.
Castle Biosciences works with all insurance providers, including Medicare, Medicaid, commercial insurers, and the VA, to secure payment for your TissueCypher test. Castle will submit your insurance claim and manage the insurance billing process on your behalf. The company also offers an industry-leading Patient Assistance Program with the belief that quality care should not depend on financial considerations.
You can get more information about insurance coverage, claims processing and financial assistance by calling 866-788-9007 and selecting option #3.